BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched two generic drugs, including first-to-market erythromycin tablets.
The Amneal erythromycin product, in 250 mg and 500 mg strengths, is a therapeutic equivalent for the reference listed drug erythromycin tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available.
“Amneal is committed to increasing access to affordable medications,” said executive vice president of commercial operations Andy Boyer. “Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options.”
The tablets are sold in 100-count bottles. Annual U.S. sales of erythromycin tablets were $84 million, according to January 2018 IQVIA market data.
Amneal also introduced tiagabine hydrochloride tablets in 2 mg, 4 mg, 12 mg and 16 mg strengths. The product is an AB-rated therapeutic equivalent for Gabitril.
Tiagabine HCl tablets are available in 30-count bottles. Annual U.S. sales of Gabitril and its generic equivalents were $30 million, according to IQVIA.